Guardant Health (NASDAQ:GH) Price Target Raised to $55.00

Guardant Health (NASDAQ:GH) had its price objective upped by JPMorgan Chase & Co. from $50.00 to $55.00 in a research note released on Friday,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other research firms have also weighed in on GH. The Goldman Sachs Group raised their price objective on Guardant Health from $36.00 to $49.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Stifel Nicolaus boosted their price target on Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Friday. Guggenheim reaffirmed a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 22nd. Sanford C. Bernstein cut their price objective on Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th. Finally, Barclays initiated coverage on Guardant Health in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $60.00 price target on the stock. Eighteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Guardant Health currently has an average rating of “Buy” and an average price target of $44.78.

Guardant Health Trading Down 9.6 %

GH opened at $42.87 on Friday. The stock has a market cap of $5.30 billion, a PE ratio of -12.04 and a beta of 1.32. The stock’s fifty day simple moving average is $40.19 and its 200 day simple moving average is $31.57. Guardant Health has a 1-year low of $15.81 and a 1-year high of $50.89.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. Equities analysts forecast that Guardant Health will post -2.9 earnings per share for the current year.

Insider Buying and Selling

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the transaction, the director now owns 2,676 shares in the company, valued at $93,660. This represents a 46.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 2,768 shares of company stock worth $98,798. 5.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. R Squared Ltd bought a new position in shares of Guardant Health during the 4th quarter worth $26,000. JNBA Financial Advisors bought a new position in shares of Guardant Health during the 3rd quarter valued at about $26,000. SBI Securities Co. Ltd. bought a new position in shares of Guardant Health during the 4th quarter valued at about $43,000. Ashton Thomas Securities LLC bought a new position in Guardant Health during the 3rd quarter worth approximately $34,000. Finally, Kimelman & Baird LLC bought a new position in Guardant Health during the 4th quarter worth approximately $58,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.